High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma

References

• Ko Y H, Kim C W, Park C S, Jang H K, Lee S S, Kim S H, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 1998; 83: 806–812
   PubMed Web of Science ®Google Scholar
• Melnyk A, Rodriguez A, Pugh W C, Cabannillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514–4520
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 76–82
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. for the Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474–2479
   PubMed Web of Science ®Google Scholar
• Kim K, Kim W S, Jung C W, Im Y H, Kang W K, Lee M H, et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 2002; 38: 75–81
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo J M, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL Classification. Ann Oncol 1998; 9: 849–855
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol – a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 16: 3025–3030
   Google Scholar
• Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, , for the Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287–1295
   PubMed Web of Science ®Google Scholar
• Vose J M, Peterson C, Bierman P J, Weisenburger D D, Linder J, Harrington D, et al. Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas. Blood 1990; 76: 424–431
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Nimer S D, Zelenetz A D, Hamlin P A, Horwitz A, Qin J, et al. Similar outcomes for chemosensitive (CS) relapsed or primary refractory peripheral T-cell lymphoma (PTCL) and diffuse large B-Cell lymphoma (DLBCL) treated with autologous transplantation (ASCT). Blood 2002; 100: 646a
   Web of Science ®Google Scholar
• Song K W, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003; 120: 978–985
   PubMed Web of Science ®Google Scholar
• Angelopoulou M K, Nademanee A, Dagis A, Molina A, Fung H C, Parker P M, et al. Comparison of outcome of high dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) in peripheral T cell lymphoma (PTCL) versus diffuse large B cell lymphoma (B-DLCL). Blood 2003; 101: 867a
   Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting – Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Ajani J A, Welch S R, Raber M N, Fields W S, Krakoff I H. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147–159
   PubMed Web of Science ®Google Scholar
• Miller A B, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Jaffe E S, Krenacs L, Kumar S, Kingma D W, Raffeld M. Extranodal peripheral T-cell and NK-cell neoplasms. Am J Clin Pathol 1999; 111: S46–S55
   PubMed Web of Science ®Google Scholar
• Ohshima K, Kobari S, Kuroiwa S, Nakanishi K, Shibuya T, Nagafuchi S, et al. Heterogeneity of systemic extra-nodal Epstein-Barr virus-associated lympho-histiocytic tumor – 10 autopsy cases of human immunodeficiency virus-negative Japanese. Pathol Res Pract 1997; 193: 257–265
   PubMed Web of Science ®Google Scholar
• Su I J, Wang C H, Cheng A L, Chen R L. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Leuk Lymphoma 1995; 19: 401–406
   PubMed Web of Science ®Google Scholar
• Cheng A L, Su I J, Chen Y C, Uen W C, Wang C H. Characteristic clinicopathologic features of Epstein-Barr virus-associated peripheral T-cell lymphoma. Cancer 1993; 72: 909–916
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Caballero M D, Gutierrez A, Marin J, Lahuerta J J, Sureda A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003; 14: 1768–1775
   PubMed Web of Science ®Google Scholar
• Blystad A K, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001; 27: 711–716
   PubMed Web of Science ®Google Scholar
• Jantunen E, Wiklund T, Juvonen E, Putkonen M, Lehtinen T, Kuittinen O, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004; 33: 405–410
   PubMed Web of Science ®Google Scholar
• Reimer P, Schertlin T, Rudiger T, Geissinger E, Roth S, Kunzmann V, et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 2004; 5: 304–311
   PubMedGoogle Scholar
• Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172–2176
   PubMed Web of Science ®Google Scholar